Repligen Corporation $RGEN Shares Bought by First Trust Advisors LP

First Trust Advisors LP grew its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 122.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 630,070 shares of the biotechnology company’s stock after buying an additional 347,294 shares during the period. First Trust Advisors LP’s holdings in Repligen were worth $74,235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. United Capital Financial Advisors LLC acquired a new stake in shares of Repligen during the 3rd quarter worth about $368,387,000. Opti Capital Management LP purchased a new stake in Repligen during the fourth quarter worth approximately $2,399,209,000. Wasatch Advisors LP acquired a new position in Repligen in the first quarter valued at approximately $146,513,000. Massachusetts Financial Services Co. MA acquired a new position in Repligen in the fourth quarter valued at approximately $199,176,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Repligen by 31.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after purchasing an additional 1,091,683 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Repligen

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.60% of the stock is owned by insiders.

Repligen Trading Down 4.1%

NASDAQ:RGEN opened at $131.96 on Friday. The company has a market capitalization of $7.44 billion, a PE ratio of 146.62, a P/E/G ratio of 2.54 and a beta of 1.06. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The stock’s 50 day moving average price is $131.68 and its 200 day moving average price is $132.60. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, research analysts anticipate that Repligen Corporation will post 1.99 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 14th. Roth Capital started coverage on shares of Repligen in a research report on Friday, April 17th. They issued a “buy” rating and a $160.00 target price on the stock. Finally, Wolfe Research began coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $165.36.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.